Trade Policy

Echoing wider sentiments in the biosimilar and generic drug industry, the IGBA has warned of the potential consequences of mercantilist tariffs on the global drug supply and their impact on industry and patients.

If medtech becomes embroiled in the EU-US trade war, access to critical and innovative medical devices will be under threat.

Indian CDMOs could consider collaborating with allies in Europe amid a focused effort via a new industry body to counter existing challenges like China’s manufacturing, regulatory and policy advantages and a shortage of funding and talent in the country even as talk of US tariffs throws a new spoke in the wheel

The US administration added another layer of confusion after its overnight pronouncements on Mexican tariffs. For medtech, the uncertainty remains, and while the potential impact on the industry might still seem to be a simple question of bilateral trade math, which in itself is huge, the ramifications go even deeper – and wider, writes Bernard Murphy.

The president says 4 March would mark the start of tariffs he initially intended to take effect on 1 February before allowing a delay for Mexico and Canada to implement border security to help curb illegal entry by immigrants and fentanyl smuggling.

US President Trump’s threat of a “25% or higher” import tariff on pharmaceuticals sends ripples through an already uncertain environment. With about half of generics sourced from India, captains of industry read between the lines

In an update to its strategy for dealing with US tariffs, Korea’s Celltrion has revealed actions taken so far, as well as outlining plans to consider moving “swiftly” to secure US manufacturing for APIs if circumstances demand.

US President Trump’s plan for a “25% or higher” tariff on pharmaceuticals promises to have a far-reaching impact, from higher prices and drug shortages to increased onshoring of manufacturing in the US. Is MAGA worth the chaos it might create for MAHA? The Indian industry shares its views.

A US tariff on imports from China raises the spectre of similar action against India, but Aurobindo, the largest generics company in the US by prescriptions dispensed, assures it has alternatives in place. While trials for an opthalmology biosimilar are delayed, supply of other biosimilars to Europe is set to begin in Q2 FY26.

Taking a broad view of big pharma share price movements as the sector reported 2024 financials, company-specific issues were complicated by geopolitical factors including Donald Trump’s tariff announcements.